These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2708556)

  • 1. Use of buspirone in the treatment of schizophrenia.
    Sovner R; Parnell-Sovner N
    J Clin Psychopharmacol; 1989 Feb; 9(1):61-2. PubMed ID: 2708556
    [No Abstract]   [Full Text] [Related]  

  • 2. An open trial of buspirone added to neuroleptics in schizophrenic patients.
    Goff DC; Midha KK; Brotman AW; McCormick S; Waites M; Amico ET
    J Clin Psychopharmacol; 1991 Jun; 11(3):193-7. PubMed ID: 2066458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study.
    Sumiyoshi T; Park S; Jayathilake K; Roy A; Ertugrul A; Meltzer HY
    Schizophr Res; 2007 Sep; 95(1-3):158-68. PubMed ID: 17628435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching patients from olanzapine or risperidone to a combination treatment using perphenazine plus buspirone: evaluation of antipsychotic efficacy and side-effects, including extrapyramidal effects and weight loss.
    Andersen TH; Bech P; Larsen NE
    Nord J Psychiatry; 2005; 59(3):205-8. PubMed ID: 16195121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of buspirone in seven schizophrenic subjects.
    Brody D; Adler LA; Kim T; Angrist B; Rotrosen J
    J Clin Psychopharmacol; 1990 Feb; 10(1):68-9. PubMed ID: 1968473
    [No Abstract]   [Full Text] [Related]  

  • 6. Intranasal buspirone.
    Cummins TK; Diamond RJ
    J Clin Psychopharmacol; 1990 Aug; 10(4):297-8. PubMed ID: 2286702
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT(1A) receptor agonist.
    Piskulić D; Olver JS; Maruff P; Norman TR
    Hum Psychopharmacol; 2009 Aug; 24(6):437-46. PubMed ID: 19637398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjunctive azapirone for schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials.
    Zheng W; Li XH; Cai DB; Yang XH; Ungvari GS; Ng CH; Ning YP; Xiang YT
    Eur Neuropsychopharmacol; 2018 Jan; 28(1):149-158. PubMed ID: 29174529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognitive enhancement in schizophrenia by buspirone: Role of serotonin
    Sumiyoshi T
    Schizophr Res; 2020 Jan; 215():455-456. PubMed ID: 31648843
    [No Abstract]   [Full Text] [Related]  

  • 10. [Specific responses to drug therapy and Leonhard classification of chronic schizophrenia].
    Ban TA; Kelwala S; Wilson WH
    Seishin Shinkeigaku Zasshi; 1983; 85(9):598-600. PubMed ID: 6676761
    [No Abstract]   [Full Text] [Related]  

  • 11. The prevalence of tardive dystonia in patients with chronic schizophrenia.
    Sachdev P
    Aust N Z J Psychiatry; 1991 Dec; 25(4):446, 448. PubMed ID: 1686546
    [No Abstract]   [Full Text] [Related]  

  • 12. A negative, double-blind, placebo-controlled, clinical trial of verapamil in chronic schizophrenia.
    Grebb JA; Shelton RC; Taylor EH; Bigelow LB
    Biol Psychiatry; 1986 Jun; 21(7):691-4. PubMed ID: 3518822
    [No Abstract]   [Full Text] [Related]  

  • 13. Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study.
    Silver H; Nassar A
    Biol Psychiatry; 1992 Apr; 31(7):698-704. PubMed ID: 1599987
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of chronic schizophrenia with cyproheptadine.
    Silver H; Blacker M; Weller MP; Lerer B
    Biol Psychiatry; 1989 Feb; 25(4):502-4. PubMed ID: 2649160
    [No Abstract]   [Full Text] [Related]  

  • 15. Increased prolactin response to buspirone in chronic fatigue syndrome.
    Sharpe M; Clements A; Hawton K; Young AH; Sargent P; Cowen PJ
    J Affect Disord; 1996 Nov; 41(1):71-6. PubMed ID: 8938208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lorazepam as an adjunct in the treatment of auditory hallucinations in a schizophrenic patient.
    Yassa R; Nastase C; Belzile L
    J Clin Psychopharmacol; 1989 Oct; 9(5):386. PubMed ID: 2794102
    [No Abstract]   [Full Text] [Related]  

  • 17. Lack of pharmacokinetic interaction between buspirone and haloperidol in patients with schizophrenia.
    Huang HF; Jann MW; Wei FC; Chang TP; Chen JS; Juang DJ; Lin SK; Lam YW; Chien CP; Chang WH
    J Clin Pharmacol; 1996 Oct; 36(10):963-9. PubMed ID: 8930784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How multiple medication use evolves and the importance of therapeutic trials: the slippery slide.
    Preskorn SH
    J Psychiatr Pract; 2008 May; 14(3):170-5. PubMed ID: 18520787
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of schizophrenia with a vasopressin analogue.
    Iager AC; Kirch DG; Bigelow LB; Karson CN
    Am J Psychiatry; 1986 Mar; 143(3):375-7. PubMed ID: 3513631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fluoxetine in chronic schizophrenia.
    Lindenmayer JP; Vakharia M; Kanofsky D
    J Clin Psychopharmacol; 1990 Feb; 10(1):76. PubMed ID: 2307741
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.